US6803461B2 - Synthesis of ceftiofur intermediate - Google Patents

Synthesis of ceftiofur intermediate Download PDF

Info

Publication number
US6803461B2
US6803461B2 US10/208,879 US20887902A US6803461B2 US 6803461 B2 US6803461 B2 US 6803461B2 US 20887902 A US20887902 A US 20887902A US 6803461 B2 US6803461 B2 US 6803461B2
Authority
US
United States
Prior art keywords
amino
cephem
thiomethyl
furylcarbonyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10/208,879
Other versions
US20030130502A1 (en
Inventor
Pramod Narayan Deshpande
Bhausaheb Pandharinath Khadangale
Surulichamy Senthil Kumar
Gautam Kumar Das
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orchid Pharma Ltd
Original Assignee
Orchid Chemicals and Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals and Pharmaceuticals Ltd filed Critical Orchid Chemicals and Pharmaceuticals Ltd
Priority to US10/208,879 priority Critical patent/US6803461B2/en
Assigned to ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED reassignment ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAS, GAUTAM K., DESHPANDE, PRAMOD N., KHADANGALE, BHAUSAHEB P., KUMAR, SURULICHAMY S.
Publication of US20030130502A1 publication Critical patent/US20030130502A1/en
Application granted granted Critical
Publication of US6803461B2 publication Critical patent/US6803461B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/187-Aminocephalosporanic or substituted 7-aminocephalosporanic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Definitions

  • the present invention discloses an improved process for the preparation of 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I)
  • Ceftiofur acid, its alkali metal, alkaline earth metal and amines salts were reported for the first time in U.S. Pat. No. 4,464,367.
  • the ceftiofur is a condensation product of 7-ACA with furyl-2-carbonylthiol and 2-(2-aminothiazol-4-yl)2-methoxyimino)acetic acid at 3 and 7 position respectively.
  • 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I) is the key intermediate which decides the quality and overall yield of the process for making the ceftiofur.
  • furyl-2-carbonylthiol belongs to the class of heterocyclic thioacids and not heterocyclic thiol.
  • the behaviour of the reaction is not similar for the thioacids as it was for thiols thereby disallowing the conditions of the U.S. Pat. No. 5,387,679 to be used in the present invention.
  • the applicant provides for the first time an improved process for condensing 7-ACA with furyl-2-carbonylthiol which is generated and used in situ in the presence of borontrifluoride in a gaseous state or its solution in an organic solvent to obtain compound of formula (I).
  • This process gives desired compound of formula (I) in excellent yield (90-95%) and high purity 98-99%).
  • the primary object of the invention is to provide an improved and commercially viable process for preparing 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid of formula (I) as an intermediate for ceftiofur.
  • Another object of the invention is to use furyl-2-carbonylthiol in situ without isolating it.
  • Yet another objective of this invention is to provide a process, this will give high yield and excellent purity of the product.
  • Still another object of the invention is to provide the use of boron trifluoride in gaseous state or its solution in an organic solvent or boron trifluoride complex for carrying out the condensation reaction at low temperature, which is convenient for commercial production.
  • the present invention provides the process for preparation of 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid (I) by the condensation of 7-aminocephalosporanic acid (II) with furyl-2-carbonylthiol (III) in the presence of borontrifluoride or its complex, in an organic solvent or mixture of solvents at 0-50° C.
  • the organic solvents used for the condensation is selected from tetrahydrofuran, methyl acetate, ethylacetate, n-propylacetate, iso-propylacetate, n-butylacetate, dichloromethane, toluene, diethylether, di-isopropylether, acetonitrile, acetic acid or mixtures thereof.
  • the boron trifluoride is used in gaseous state, as well as its complex with diethyl ether, in solvents such as acetonitrile, ethylacetate and other compatible solvents. Boron trifluoride is used in 4-8 mole equivalents for 1.0 moles of 7-ACA.
  • the reaction is carried out preferably at a temperature in the range of 30-40° C.
  • the reaction is monitored for completion of the reaction by measuring the content of 7-ACA in the reaction mixture.
  • the content of the 7-ACA should be less than 1%.
  • the content of the 7-ACA reaches to less than 1% within 3-5 hours.
  • the mass is poured into water and pH is adjusted to 3-4 by addition of a base.
  • the base used is selected from aqueous ammonia, ammonium hydroxide, sodium hydroxide, sodium carbonate, triethylamine, tributylamine.
  • the solid product is filtered and washed with a solvent and water mixture.
  • the solvent used is selected from tetrahydrofuran, methyl acetate, ethylacetate, n-propylacetate, iso-propylacetate, n-butylacetate, dichloromethane, toluene, diethylether, di-isopropylether, acetonitrile, acetic acid or mixtures thereof
  • furyl-2-carbonylthiol is prepared in situ from furyl-2-carbonyl chloride/sodium sulphide or furyl-2-carbonyl chloride/sodium hydrogen sulphide.
  • ethylacetate 350 ml
  • boron trifluoride gas (124.0 g) is purged into it.
  • 7-Amino-cephalosporanic acid (91.0 g) is added at 10.0° C. into this solution of borontrifluoride followed by the addition of furyl-2-carbonylthiol solution in ethylacetate (prepared above).
  • the reaction is completed after stirring for 4-5 hr at 30-40° C., after completion of the reaction, the mixture is poured into mixture of ice cold water.
  • the pH of the solution is adjusted to 3.45-3.55 by addition of aqueous ammonia.
  • boron trifluoride gas (85.0 g) is purged into it.
  • 7-Amino-cephalosporanic acid (60.6 g) is added at 10.0° C. into this solution of borontrifluoride followed by the addition of furyl-2-carbonylthiol solution in ethylacetate (prepared above).
  • the reaction is completed after stirring for 4-5 hr at 30-40° C. After completion of the reaction mass, is poured into ice cold water. The pH of the solution is adjusted to 3.45-3.55 by addition of aq. ammonia.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention relates to a process for preparation of 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid (I) by the condensation of 7-aminocephalosporanic acid (II) with furyl-2-carbonylthiol (III) in the presence of borontrifluoride or its complex, in an organic solvent or mixture of solvents at 0-50° C.

Description

This application is a continuation in part of U.S. application Ser. No. 10/035,178 filed on Jan. 4, 2002.
FIELD OF THE INVENTION
The present invention discloses an improved process for the preparation of 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I)
Figure US06803461-20041012-C00001
by the condensation of 7-amino cephalosporanic acid (7-ACA) represented by formula (II) with furyl-2-carbonylthiol represented by formula (III) using borontrifluoride or its complex as condensing agent.
Figure US06803461-20041012-C00002
BACKGROUND OF THE INVENTION
Ceftiofur is the generic name given to compound of formula (IV)
Figure US06803461-20041012-C00003
Ceftiofur acid, its alkali metal, alkaline earth metal and amines salts were reported for the first time in U.S. Pat. No. 4,464,367. The ceftiofur is a condensation product of 7-ACA with furyl-2-carbonylthiol and 2-(2-aminothiazol-4-yl)2-methoxyimino)acetic acid at 3 and 7 position respectively. 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I) is the key intermediate which decides the quality and overall yield of the process for making the ceftiofur.
To our surprise there are very few methods reported in the literature for the synthesis of 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid of the formula (I). The first report for the synthesis of this intermediate appeared in the U.S. Pat. No. 4,464,367 where the method used for the condensation was taken from a reference from the Journal of Antibiotics 27, 573-8, (1974). These references are about the condensation carried out at a pH of 6.4 using phosphate buffer. The reaction time is very long by following this method and 47% yield is reported for the reaction. These limitations make the process unfavorable for the commercial exploitation.
Another method was disclosed in WO patent 87/01117, which is also merely an extension of the earlier mentioned patent. The condensation was affected by reaction of sodium thiofuroate and 7-ACA at a temperature of 65° C. in aqueous medium at an pH of 6.4. Cephalosporins are known to decompose at high temperature and moreover using the process using this process, the reaction is not completed and yields are also very poor (about 45% and in addition the reaction takes longer time, for example, even after several hours the reaction is incomplete).
Looking at all these problems, a method for the condensation under non-aqueous was reported in U.S. Pat. No. 5,387,679 where condensation of 7-ACA with heterocyclic thiols in the presence of complex of borontrifluoride with dialkyl carbonate was carried out to provide intermediates which are used in the synthesis of cephalosporin antibiotics. When this method was applied for the condensation of 7-ACA and furyl-2-carbonylthiol the reaction mixture was associated with several impurities which could not be separated even during the final purification step. Later on, after several experimentations we found that the stability of furyl-2-carbonylthiol in its solid form is not good, since furyl-2-carbonylthiol belongs to the class of heterocyclic thioacids and not heterocyclic thiol. The behaviour of the reaction is not similar for the thioacids as it was for thiols thereby disallowing the conditions of the U.S. Pat. No. 5,387,679 to be used in the present invention.
In order to overcome the problem, the applicant provides for the first time an improved process for condensing 7-ACA with furyl-2-carbonylthiol which is generated and used in situ in the presence of borontrifluoride in a gaseous state or its solution in an organic solvent to obtain compound of formula (I). This process gives desired compound of formula (I) in excellent yield (90-95%) and high purity 98-99%).
OBJECTS OF THE INVENTION
The primary object of the invention is to provide an improved and commercially viable process for preparing 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid of formula (I) as an intermediate for ceftiofur.
Another object of the invention is to use furyl-2-carbonylthiol in situ without isolating it.
Yet another objective of this invention is to provide a process, this will give high yield and excellent purity of the product.
Still another object of the invention is to provide the use of boron trifluoride in gaseous state or its solution in an organic solvent or boron trifluoride complex for carrying out the condensation reaction at low temperature, which is convenient for commercial production.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides the process for preparation of 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid (I) by the condensation of 7-aminocephalosporanic acid (II) with furyl-2-carbonylthiol (III) in the presence of borontrifluoride or its complex, in an organic solvent or mixture of solvents at 0-50° C.
The sequence of the reaction is shown below:
Figure US06803461-20041012-C00004
DETAILED DESCRIPTION OF THE INVENTION
In an embodiment the organic solvents used for the condensation is selected from tetrahydrofuran, methyl acetate, ethylacetate, n-propylacetate, iso-propylacetate, n-butylacetate, dichloromethane, toluene, diethylether, di-isopropylether, acetonitrile, acetic acid or mixtures thereof.
In still another embodiment, the boron trifluoride is used in gaseous state, as well as its complex with diethyl ether, in solvents such as acetonitrile, ethylacetate and other compatible solvents. Boron trifluoride is used in 4-8 mole equivalents for 1.0 moles of 7-ACA.
In yet another embodiment the reaction is carried out preferably at a temperature in the range of 30-40° C. The reaction is monitored for completion of the reaction by measuring the content of 7-ACA in the reaction mixture. The content of the 7-ACA should be less than 1%. The content of the 7-ACA reaches to less than 1% within 3-5 hours. After completion of reaction, the mass is poured into water and pH is adjusted to 3-4 by addition of a base. The base used is selected from aqueous ammonia, ammonium hydroxide, sodium hydroxide, sodium carbonate, triethylamine, tributylamine. The solid product is filtered and washed with a solvent and water mixture. The solvent used is selected from tetrahydrofuran, methyl acetate, ethylacetate, n-propylacetate, iso-propylacetate, n-butylacetate, dichloromethane, toluene, diethylether, di-isopropylether, acetonitrile, acetic acid or mixtures thereof
In yet another embodiment there is provided a process for the preparation of ceftiofur using the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I) prepared by a process described above by conventional methods.
In still yet another embodiment, furyl-2-carbonylthiol is prepared in situ from furyl-2-carbonyl chloride/sodium sulphide or furyl-2-carbonyl chloride/sodium hydrogen sulphide.
The invention is illustrated with following examples, which are provided by way of illustration only and should not be construed to limit the scope of the invention.
EXAMPLE—I
7-Amino-3-(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid
Sodium sulfide (54.6 g) is charged to water (600 ml) and furyl-2-carbonylchloride (50.0 g) is added in 1.0 hr at temperature of 20° C. Ethyl acetate is added to it and pH of the mass is adjusted to 1.0 using hydrochloric acid. The organic layer is separated, dried over anhydrous sodium sulphate, filtered to yield furyl-2-carbonylthiol in ethylacetate.
In an another flask ethylacetate (350 ml) is charged and boron trifluoride gas (124.0 g) is purged into it. 7-Amino-cephalosporanic acid (91.0 g) is added at 10.0° C. into this solution of borontrifluoride followed by the addition of furyl-2-carbonylthiol solution in ethylacetate (prepared above). The reaction is completed after stirring for 4-5 hr at 30-40° C., after completion of the reaction, the mixture is poured into mixture of ice cold water. The pH of the solution is adjusted to 3.45-3.55 by addition of aqueous ammonia. The solid precipitated is filtered and washed with mixture ethylacetate to get of 7-amino-3-(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid (110.0 g) with 98-99% HPLC purity.
EXAMPLE—II
7-Amino-3-(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid
Sodium sulfide (36.4 g) is charged to water (400 ml) and furyl-2-carbonylchloride (33.3.0 g) is added in 1.0 hr at temperature 20° C. Ethyl acetate is added to it and pH of the mass is adjusted to 1.0 using hydrochloric acid. The organic layer is separated, dried over anhydrous sodium sulphate, filtered to yield furyl-2-carbonylthiol in ethylacetate.
In an another flask containing acetonitrile (350 ml), boron trifluoride gas (85.0 g) is purged into it. 7-Amino-cephalosporanic acid (60.6 g) is added at 10.0° C. into this solution of borontrifluoride followed by the addition of furyl-2-carbonylthiol solution in ethylacetate (prepared above). The reaction is completed after stirring for 4-5 hr at 30-40° C. After completion of the reaction mass, is poured into ice cold water. The pH of the solution is adjusted to 3.45-3.55 by addition of aq. ammonia. The solid precipitated is filtered and washed with mixture of water and acetonitrile to get of 7-amino-3-(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid (69.0 g) with 97-98% HPLC purity.
EXAMPLE—III
7-Amino-3-(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid
Sodium sulfide (54.6 g) is charged to water (600 ml) and furyl-2-carbonylchloride (50.0 g) is added in 1.0 hr at temperature of 20° C. Ethyl acetate is added to it and pH of the mass was adjusted to 1.0 using hydrochloric acid. The organic layer is separated, dried over anhydrous sodium sulphate, filtered to yield furyl-2-carbonylthiol in ethylacetate.
In an another flask containing acetonitrile (350 ml), 7-amino-cephalosporanic acid (91.0 g) is added at room temperature followed by addition of 45-48% boron trifluoride etherate (275.5 ml) at 10.0° C. To this is added furyl-2-carbonylthiol solution in ethylacetate (prepared above). The reaction is completed after stirring for 4-5 hr at 40-50° C. After completion, the reaction mixture is poured into ice cold water. The pH of the solution is adjusted to 3.45-3.55 by addition of sodium carbonate solution. The solid precipitated is filtered and washed with mixture of water and ethylacetate to get 7-amino-3-(2-furanylcarbonylthiomethyl]-3-cephem-4-carboxylic acid (104.0 g) with 97-98% HPLC purity.
EXAMPLE—IV
7-Amino-3-(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid
30.0 g of sodium hydrogen sulfide is dissolved in 350 ml. of water at 18-25° C. 27.5 g of 2-furoyl chloride is added slowly in 40 to 45 mins. at 18-25° C. and stir for 10 mins. at same temperature. Ethylacetate (250 ml) is added and the pH of the reaction mass is maintained below 1.0 with hydrochloric acid. Separate the organic layer and water (175 ml) is added. The pH is adjusted by sodium bicarbonate (19 g) to 7.0 to 7.5. The aqueous layer is separated and ethyl acetate (100 ml) is added. The pH is maintained adjusted to 0.9 to 1.0 with hydrochloric acid and stir for 15 min and separate the organic layer.
In an another flask 200 ml of ethylacetate is charged and cooled to 0 C. 68.5 g boron trifluoride gas is purged into it. EDTA (1.0 g) is added to the reaction mass and the temperature is raised to 15 C and stirred for 10 min. 50.0 g of the 7-Amino-cephalosporanic acid is added at 10° C. into this solution of borontrifluoride followed by the addition of furyl-2-carbonylthiol solution in ethylacetate (prepared earlier). The reaction is completed after stirring for 3-4 hr at 30-40° C. The mixture is then cooled to 15.degree. C. and 285 ml of cold water is added followed by freshly prepared solution of 1 g of sodium metabisulphite in 50 ml water and 0.3 g EDTA disodium in 50 ml water. pH of the solution is adjusted to 3.45-3.55 by addition of aq. ammonia. The solid precipitated is filtered and washed with ethylacetate (50 ml) to get of 7-amino-3-(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid with 98-99% HPLC purity.

Claims (39)

We claim:
1. A process for preparation of 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I)
Figure US06803461-20041012-C00005
by the condensation of 7-aminocephalosporanic acid (II)
Figure US06803461-20041012-C00006
with furyl-2-carbonylthiol (III)
Figure US06803461-20041012-C00007
in the presence of a borontrifluoride complex, in an organic solvent or mixture of solvents at 0-50° C.
2. A process as claimed in claim 1, wherein the organic solvent used for carrying out the condensation reaction is selected from tetrahydrofuran, methyl acetate, ethylacetate, n-propylacetate, iso-propylacetate, n-butylacetate, dichloromethane, toluene, diethylether, di-isopropylether, acetonitrile or mixtures thereof.
3. A process as claimed in claim 1, wherein the borontrifluoride complex is borontrifluoride etherate.
4. A process for the preparation of ceftiofur, comprising:
preparing 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I) by the process of claim 1; and
preparing ceftiofur from the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid.
5. A process for the preparation of ceftiofur, comprising:
preparing 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I) by the process of claim 2; and
preparing ceftiofur from the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid.
6. A process for the preparation of ceftiofur, comprising:
preparing 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I) by the process of claim 3; and
preparing ceftiofur from the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid.
7. A process for preparation of 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I),
Figure US06803461-20041012-C00008
the said process comprising the step of condensing 7-aminocephalosporanic acid (II) with furyl-2-carbonylthiol (III) in the presence of borontrifluoride or its complex at 20-50° C. in an organic solvent to form a reaction mixture, and isolating the compound of formula (I),
Figure US06803461-20041012-C00009
wherein the reaction mixture of the condensing step is poured into ice cold water, pH of the resulting solution is adjusted to 3-4 with a base to precipitate a solid, the solid is washed with a mixture of water and organic solvent, and the solid is dried at a temperature range of 40°-45° C. under vacuum.
8. A process as claimed in claim 7, wherein the condensing step is performed at a temperature range of 30°-35° C.
9. A process as claimed in claim 3, wherein the pH of the solution is adjusted to 3.45-3.55.
10. A process as claimed in claim 7, wherein furyl-2-carbonylthiol of formula (III) is used in the form of a solution in which said furyl-2-carbonylthiol was prepared, said solution comprising an organic solvent selected from the group consisting of ethylacetate, methyl acetate, propyl acetate, dichloromethane, toluene, diethyl ether, di-isopropyl ether and mixtures thereof.
11. A process as claimed in claim 7, wherein the organic solvent used in the condensing step is selected from the group consisting of ethylacetate, methyl acetate, propyl acetate, dichloromethane, toluene, diethyl ether, di-isopropyl ether, acetonitrile, acetic acid and mixtures thereof.
12. A process as claimed in claim 7, wherein the borontrifluoride is used in a gaseous form or in the form of its solution in an organic solvent selected from ethyl acetate, acetonitrile, methyl acetate, propyl acetate, dichloromethane, toluene, diethyl ether, di-isopropyl ether and mixtures thereof.
13. A process as claimed in claim 7, wherein 3-8 moles of borontrifluoride are used with respect to 7-aminocephalosporanic acid.
14. A process as claimed in claim 7, wherein the base is selected from the group consisting of ammonium hydroxide, sodium hydroxide, and sodium carbonate.
15. A process as claimed in claim 7, wherein the organic solvent used for washing the final product comprises at least one member selected from the group consisting of acetonitrile, ethylacetate, acetone, methyl acetate, propyl acetate, dichloromethane, toluene, diethyl ether, di-isopropyl ether and mixtures thereof.
16. A process as claimed in claim 7, wherein the organic solvent used in the condensing step comprises ethyl acetate.
17. A process as claimed in claim 7, wherein the borontrifluoride is used in a gaseous form.
18. A process as claimed in claim 7, wherein 4.5 moles of borontrifluoride are used with respect to each mole of 7-aminocephalosporanic acid.
19. A process as claimed in claim 7, wherein the base comprises ammonium hydroxide.
20. A process for preparation of 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I),
Figure US06803461-20041012-C00010
the said process comprising the step of condensing 7-aminocephalosporanic acid (II) with furyl-2-carbonylthiol (III) in the presence of borontrifluoride in a gaseous form, or its complex, at 20-50° C. in an organic solvent to form a reaction mixture, and isolating the compound of formula (I).
Figure US06803461-20041012-C00011
21. A process as claimed in claim 20, wherein the condensing step is performed at a temperature range of 30°-35° C.
22. A process as claimed in claim 20, wherein the reaction mixture of the condensing step is poured into ice cold water, and the pH of the solution is adjusted to 3-4 with a base to precipitate a solid.
23. A process as claimed in claim 22, wherein the pH of the solution is adjusted to 3.45-3.55.
24. A process as claimed in claim 22, wherein the solid obtained by precipitation is washed with a mixture of water and organic solvent, and the solid is dried at a temperature range of 40°-45° C. under vacuum.
25. A process as claimed in claim 20, wherein furyl-2-carbonylthiol of formula (III) is used in the form of a solution in which said furyl-2-carbonylthiol was prepared, said solution comprising an organic solvent selected from the group consisting of ethylacetate, methyl acetate, propyl acetate, dichloromethane, toluene, diethyl ether, di-isopropyl ether and mixtures thereof.
26. A process as claimed in claim 20, wherein the organic solvent used in the condensing step is selected from the group consisting of ethylacetate, methyl acetate, propyl acetate, dichloromethane, toluene, diethyl ether, di-isopropyl ether, acetonitrile, acetic acid and mixtures thereof.
27. A process as claimed in claim 20, wherein 3-8 moles of borontrifluoride are used with respect to 7-aminocephalosporanic acid.
28. A process as claimed in claim 22, wherein the base is selected from the group consisting of ammonium hydroxide, sodium hydroxide, and sodium carbonate.
29. A process as claimed in claim 24, wherein the organic solvent used for washing the final product comprises at least one member selected from the group consisting of acetonitrile, ethylacetate, acetone, methyl acetate, propyl acetate, dichloromethane, toluene, diethyl ether, di-isopropyl ether and mixtures thereof.
30. A process as claimed in claim 20, wherein the organic solvent used in the condensing step comprises ethyl acetate.
31. A process as claimed in claim 20, wherein 4.5 moles of borontrifluoride are used with respect to each mole of 7-aminocephalosporanic acid.
32. A process as claimed in claim 22, wherein the base comprises ammonium hydroxide.
33. A process for the preparation of ceftiofur, comprising:
preparing 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I) by the process of claim 7; and
preparing ceftiofur from the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid.
34. A process for the preparation of ceftiofur, comprising:
preparing 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I) by the process of claim 20; and
preparing ceftiofur from the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid.
35. A process as claimed in claim 4, wherein the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid is reacted with 2-(2-aminothiazol-4-yl)2-methoxyimino acetic acid to form the ceftiofur.
36. A process as claimed in claim 5, wherein the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid is reacted with 2-(2-aminothiazol-4-yl)2-methoxyimino acetic acid to form the ceftiofur.
37. A process as claimed in claim 6, wherein the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid is reacted with 2-(2-aminothiazol-4-yl)2-methoxyimino acetic acid to form the ceftiofur.
38. A process as claimed in claim 33, wherein the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid is reacted with 2-(2-aminothiazol-4-yl)2-methoxyimino acetic acid to form the ceftiofur.
39. A process as claimed in claim 34, wherein the 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid is reacted with 2-(2-aminothiazol-4-yl)2-methoxyimino acetic acid to form the ceftiofur.
US10/208,879 2002-01-04 2002-08-01 Synthesis of ceftiofur intermediate Expired - Fee Related US6803461B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/208,879 US6803461B2 (en) 2002-01-04 2002-08-01 Synthesis of ceftiofur intermediate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/035,178 US20030135041A1 (en) 2002-01-04 2002-01-04 Synthesis of ceftiofur intermediate
US10/208,879 US6803461B2 (en) 2002-01-04 2002-08-01 Synthesis of ceftiofur intermediate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/035,178 Continuation-In-Part US20030135041A1 (en) 2002-01-04 2002-01-04 Synthesis of ceftiofur intermediate

Publications (2)

Publication Number Publication Date
US20030130502A1 US20030130502A1 (en) 2003-07-10
US6803461B2 true US6803461B2 (en) 2004-10-12

Family

ID=21881126

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/035,178 Abandoned US20030135041A1 (en) 2002-01-04 2002-01-04 Synthesis of ceftiofur intermediate
US10/208,879 Expired - Fee Related US6803461B2 (en) 2002-01-04 2002-08-01 Synthesis of ceftiofur intermediate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/035,178 Abandoned US20030135041A1 (en) 2002-01-04 2002-01-04 Synthesis of ceftiofur intermediate

Country Status (12)

Country Link
US (2) US20030135041A1 (en)
EP (1) EP1463734B1 (en)
KR (1) KR100847339B1 (en)
CN (1) CN1310923C (en)
AT (1) ATE294183T1 (en)
AU (1) AU2002367103A1 (en)
BR (1) BR0215473A (en)
CA (1) CA2471310C (en)
DE (1) DE60203944T2 (en)
ES (1) ES2242044T3 (en)
MX (1) MXPA04006587A (en)
WO (1) WO2003055893A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207912A1 (en) * 2002-10-29 2008-08-28 Lupin Limited Method for manufacture of ceftiofur
US20080221076A1 (en) * 2005-10-12 2008-09-11 Orchid Chemicals And Pharmaceuticals Limited Crystalline Sodium Salt of Cephalosporin Antibiotic
US20110059933A1 (en) * 2005-10-12 2011-03-10 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
US20110136777A1 (en) * 2008-08-22 2011-06-09 Orchid Chemicals And Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100502390B1 (en) * 2001-09-07 2005-07-19 주식회사 엘지생명과학 Process for preparing cephalosporinic acid
CN102234289B (en) * 2010-05-02 2013-07-10 青岛科技大学 Novel method for preparing ceftiofur intermediate
CN103804394A (en) * 2014-01-24 2014-05-21 瑞普(天津)生物药业有限公司 Preparation method of ceftiofur intermediate
CN108623617B (en) * 2017-03-22 2021-04-02 蒋辉 Preparation method of ceftiofur intermediate
CN112645965B (en) * 2020-12-22 2022-03-25 浙江华尔成生物药业股份有限公司 Preparation process of ceftiofur sodium for vacuum freeze-drying injection
CN114409676A (en) * 2021-12-24 2022-04-29 河南立诺制药有限公司 Preparation method of 7-ACF
CN116535421A (en) * 2023-07-04 2023-08-04 齐鲁晟华制药有限公司 Synthesis method of ceftiofur sodium

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115645A (en) 1977-05-10 1978-09-19 Eli Lilly And Company Decolorizing process for 7-amino-3-(((2-methyl-1,3,4-thiadiazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid
US4144391A (en) 1977-03-07 1979-03-13 Eli Lilly And Company Cephalosporin displacement reaction
US4317907A (en) 1977-02-08 1982-03-02 Toyama Chemical Co., Ltd. Process for producing 7-(substituted)amino-3-substituted thiomethyl cephem carboxylic acids
US4463173A (en) 1979-12-24 1984-07-31 Ici Pharma Cephalosporin derivatives
US4464367A (en) 1980-03-26 1984-08-07 Sanofi Cephalosporin derivatives, process for preparation thereof and drugs containing said derivatives usable as antibiotics
US4472574A (en) 1981-05-22 1984-09-18 Hoffman-La Roche Inc. Process for the manufacture of a cephem carboxylic acid derivative
US4937330A (en) 1985-08-12 1990-06-26 The Upjohn Company Conversion of cephalosporin hydrohalide salt to alkali metal salt
US5387679A (en) 1991-07-15 1995-02-07 Antibioticos S.P.A. Process for the preparation of cephalosporins intermediates
US5580978A (en) 1985-06-03 1996-12-03 Biochemie Gesellschaft M.B.H. Process for the production of 7-ACA derivatives
US5597914A (en) 1993-10-22 1997-01-28 Biochemie Gesellschaft M.B.H. Process for the production of cephalosporins
US5700932A (en) 1996-07-19 1997-12-23 Cheil Jedang Co. Process for preparing cephem derivative
US5869649A (en) 1996-03-18 1999-02-09 Ranbaxy Laboratories Ltd. Process for producing cephalosporin antibiotics
WO2001008633A2 (en) 1999-07-30 2001-02-08 Ranbaxy Laboratories Limited An improved form of form i celiprolol hydrochloride
US6214997B1 (en) 1998-06-01 2001-04-10 Ranbaxy Laboratories Limited Process for the preparation of crystalline (Z)-2-(2-tert.-butoxycarbonylprop-2-oxyimino)-2-(2-triphenylmethylaminothiazol-4-yl) acetic acid in association with N,N-dimethylformamide
US6235896B1 (en) 1998-03-30 2001-05-22 Ranbaxy Laboratories Limited Process for the preparation of cefuroxime
WO2002006289A1 (en) 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Process for the preparation of highly pure crystalline (r,s) - cefuroxime axetil
US6384213B1 (en) 1998-10-23 2002-05-07 Ranbaxy Laboratories Limited Process for preparing a pure, pharmacopoeial grade amorphous form of cefuroxime axetil
US20020065412A1 (en) 2000-11-27 2002-05-30 Uthira Kumar Cephalosporin compound and a process for its preparation
US6458949B1 (en) 2000-08-14 2002-10-01 Aurobindo Pharma Limited Ceftiofur, its intermediate and a process for the preparation of the same
WO2002094816A1 (en) 2001-05-18 2002-11-28 Aurobindo Pharma Limited Process for the crystallization of losartan potassium

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191123B1 (en) * 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317907A (en) 1977-02-08 1982-03-02 Toyama Chemical Co., Ltd. Process for producing 7-(substituted)amino-3-substituted thiomethyl cephem carboxylic acids
US4385178A (en) 1977-02-08 1983-05-24 Toyama Chemical Co., Ltd. Process for producing 7-(substituted)amino-3-substituted thiomethyl cephem carboxylic acids
US4144391A (en) 1977-03-07 1979-03-13 Eli Lilly And Company Cephalosporin displacement reaction
US4115645A (en) 1977-05-10 1978-09-19 Eli Lilly And Company Decolorizing process for 7-amino-3-(((2-methyl-1,3,4-thiadiazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid
US4463173A (en) 1979-12-24 1984-07-31 Ici Pharma Cephalosporin derivatives
US4464367A (en) 1980-03-26 1984-08-07 Sanofi Cephalosporin derivatives, process for preparation thereof and drugs containing said derivatives usable as antibiotics
US4472574A (en) 1981-05-22 1984-09-18 Hoffman-La Roche Inc. Process for the manufacture of a cephem carboxylic acid derivative
US5580978A (en) 1985-06-03 1996-12-03 Biochemie Gesellschaft M.B.H. Process for the production of 7-ACA derivatives
US4937330A (en) 1985-08-12 1990-06-26 The Upjohn Company Conversion of cephalosporin hydrohalide salt to alkali metal salt
US5387679A (en) 1991-07-15 1995-02-07 Antibioticos S.P.A. Process for the preparation of cephalosporins intermediates
US5597914A (en) 1993-10-22 1997-01-28 Biochemie Gesellschaft M.B.H. Process for the production of cephalosporins
US5869649A (en) 1996-03-18 1999-02-09 Ranbaxy Laboratories Ltd. Process for producing cephalosporin antibiotics
US5700932A (en) 1996-07-19 1997-12-23 Cheil Jedang Co. Process for preparing cephem derivative
US6235896B1 (en) 1998-03-30 2001-05-22 Ranbaxy Laboratories Limited Process for the preparation of cefuroxime
US6214997B1 (en) 1998-06-01 2001-04-10 Ranbaxy Laboratories Limited Process for the preparation of crystalline (Z)-2-(2-tert.-butoxycarbonylprop-2-oxyimino)-2-(2-triphenylmethylaminothiazol-4-yl) acetic acid in association with N,N-dimethylformamide
US6384213B1 (en) 1998-10-23 2002-05-07 Ranbaxy Laboratories Limited Process for preparing a pure, pharmacopoeial grade amorphous form of cefuroxime axetil
WO2001008633A2 (en) 1999-07-30 2001-02-08 Ranbaxy Laboratories Limited An improved form of form i celiprolol hydrochloride
WO2002006289A1 (en) 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Process for the preparation of highly pure crystalline (r,s) - cefuroxime axetil
US6458949B1 (en) 2000-08-14 2002-10-01 Aurobindo Pharma Limited Ceftiofur, its intermediate and a process for the preparation of the same
US20020065412A1 (en) 2000-11-27 2002-05-30 Uthira Kumar Cephalosporin compound and a process for its preparation
US6476220B2 (en) 2000-11-27 2002-11-05 Aurobindo Pharma Limited Process for the preparation of furaca
WO2002094816A1 (en) 2001-05-18 2002-11-28 Aurobindo Pharma Limited Process for the crystallization of losartan potassium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
John M. Essery et al., "3-Acylthiomethyl Cephalosporins", The Journal of Antibodies, vol. 27, No. 8, pp. 573-578, Aug., 1974, Syracuse, New York.

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207912A1 (en) * 2002-10-29 2008-08-28 Lupin Limited Method for manufacture of ceftiofur
US20080221076A1 (en) * 2005-10-12 2008-09-11 Orchid Chemicals And Pharmaceuticals Limited Crystalline Sodium Salt of Cephalosporin Antibiotic
US20110059933A1 (en) * 2005-10-12 2011-03-10 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
US8212024B2 (en) * 2005-10-12 2012-07-03 Orchid Chemicals & Pharmaceuticals Ltd. Crystalline sodium salt of cephalosporin antibiotic
US8470809B2 (en) * 2005-10-12 2013-06-25 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
US20110136777A1 (en) * 2008-08-22 2011-06-09 Orchid Chemicals And Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
US8431562B2 (en) * 2008-08-22 2013-04-30 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic

Also Published As

Publication number Publication date
DE60203944T2 (en) 2006-02-23
CN1639169A (en) 2005-07-13
US20030130502A1 (en) 2003-07-10
CN1310923C (en) 2007-04-18
BR0215473A (en) 2004-11-30
DE60203944D1 (en) 2005-06-02
US20030135041A1 (en) 2003-07-17
MXPA04006587A (en) 2005-07-13
WO2003055893A1 (en) 2003-07-10
ES2242044T3 (en) 2005-11-01
CA2471310C (en) 2011-02-22
ATE294183T1 (en) 2005-05-15
EP1463734A1 (en) 2004-10-06
CA2471310A1 (en) 2003-07-10
EP1463734B1 (en) 2005-04-27
AU2002367103A1 (en) 2003-07-15
KR100847339B1 (en) 2008-07-21
KR20040098628A (en) 2004-11-20

Similar Documents

Publication Publication Date Title
US7825241B2 (en) Cefdinir intermediate
US6388070B1 (en) Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds
US6803461B2 (en) Synthesis of ceftiofur intermediate
US20060135761A1 (en) Novel intermediates for synthesis of cephalosporins and process for preparation of such intermediates
US7741478B2 (en) Salts in the preparation of cephalosporin antibiotics
GB2110688A (en) A process for preparing 3-alkoxymethylcephalosporin derivatives
US6800756B2 (en) Method for the preparation of ceftiofur sodium and its intermediates
US6610845B1 (en) Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds
WO2005016936A2 (en) Process for selective preparation of z-isomer of cefditoren and pharmaceutically acceptable salts and esters thereof
KR910000238B1 (en) Process for preparing thiazole derivatives
US6448393B1 (en) Process for producing 3-cephem compounds
US7335767B2 (en) Method for preparation of ceftiofur and salts thereof
US4284767A (en) Process for preparing 3-carbamoyloxymethyl cephalosporins
JP2003511455A (en) Method for producing 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid
WO2003059914A1 (en) An improved synthesis of ceftiofur intermediate
US4304909A (en) Process for producing 7-(D(-)-α-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-α-(4-hydroxyphenyl)acetamido)-3-(5-(1-methyl-1,2,3,4-tetrazolyl)thiomethyl)-.DELTA.3 -cephem-4-carboxylic acid and a pharmaceutically acceptable salt thereof
US20060252928A1 (en) Process for the preparation of cefoxitin

Legal Events

Date Code Title Description
AS Assignment

Owner name: ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED, INDI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DESHPANDE, PRAMOD N.;KHADANGALE, BHAUSAHEB P.;KUMAR, SURULICHAMY S.;AND OTHERS;REEL/FRAME:013445/0954

Effective date: 20020923

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20161012